Investor Type | Firm |
Type of Fund | Private Equity Fund |
Industries | BioTech • Medical Devices (& Hospital Services) • Life Science |
Stages | Seed, Startup, Early Stage |
Investing | United States • Canada • Italy • Spain • Sweden • China • Netherlands • Belgium • Europe • Asia |
MedSciences Capital Management B.V., operating under the name Fort Point Capital, is a private equity firm located at 185 Dartmouth Street, 6th Floor, Boston, Massachusetts. They specialize in equity investments and are known for their focus on seed, startup, and early-stage companies within the BioTech, Medical Devices, Hospital Services, and Life Science industries. As a private equity fund, their investment strategy is centered on middle-market service-oriented companies, with an enterprise value of up to $125 million and up to $50 million in equity investments. They are particularly interested in control buyouts and add-ons, targeting family or founder-owned businesses, management buyouts, and recapitalizations. Fort Point Capital prioritizes companies that demonstrate a strong management team, customer loyalty, high margins, stable earnings, robust cash flow, and identifiable avenues for growth. They seek to build great companies by actively seeking opportunities in various industry sectors, including but not limited to Business Services, IT Services & Software, Transportation & Logistics, Value-added Distribution, Marketing & Media Services, Professional Services/Training & Education, Field & Route-based Services, and Industrial, Testing & Engineering Healthcare. Since their inception in 2010, they have raised over $625 million in committed capital and invested in more than 50 companies across three funds. Fort Point Capital's growth support includes strategic planning, accretive acquisitions, management augmentation, enhancing sales & marketing, investing in technology, pricing strategy, geographic expansion, and organizational design. They report an average revenue growth of 111% and EBITDA growth of 87% during the investment period, with an average of 2.5 accretive add-on acquisitions per portfolio company.